INTRODUCTION
Mature trophozoites stage, the later intra-erythrocytic forms of Plasmodium falciparum, are bound in the deep micro-vasculature, primarily to endothelial cells (cytoadherence) and to erythrocytes (rosetting) while ring stage trophozoites circulate in the peripheral blood. The sequestration of pRBC and RBC is suggested to be mediated by Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), a parasite derived polypeptide expressed at the surface of the infected pRBC. The resulting binding of pRBC in the inner organs 1 helps the parasite to hide from the immune system and withdraw from splenic clearance. Yet, binding of the pRBC may be lethal to the parasite since excessive sequestration may cause severe malaria and the death of its human host.
PfEMP1 is a high molecular weight (200-350 kDa) transmembrane polypeptide consisting of four to seven extra cellular domains encoded by the var gene family. 2, 3 PfEMP1 mediates the sequestration of pRBC through interactions with receptors such as CD36, PECAM-1/CD31, ICAM-1, IgG, and IgM. [4] [5] [6] [7] [8] [9] [10] [11] [12] Lectin-like interactions 13 of PfEMP1 has been described with glycans such as the bloodgroup A antigen 14, 15 , heparan sulfate (HS) like glycosaminoglycans (GAGs) present on uninfected erythrocytes 16, 17 and chondroitin sulfate (CS), a galactosaminoglycan.
Indeed, CS of the A type (CSA), containing 4-O-sulfated glucosamine units, has been
found to act as a receptor for pRBC binding in the placenta 18 and in the microvasculature. 19 GAGs are long, linear carbohydrate chains attached to a core protein, forming a proteoglycan. HS is one such GAG composed of alternating glucosamine and uronic acid residues in a repeating disaccharide unit (-4GlcA 1-4GlcNAc 1-). During
biosynthesis this backbone becomes variably modified by N-deacetylation/N-sulfation
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From 5 and C5 epimerization of the glucuronic acid to iduronic acid, followed by O-sulfation at C2 of the uronic acid, and C3 and C6 of the glucosamine unit. Due to biosynthetic constraints, HS-chains are modified to different degrees and the modified units, especially the sulfate groups, are unevenly distributed along the chain. Thus, HS in different species and tissues express distinct molecular characteristics. [20] [21] [22] The related molecule heparin, which can be considered a highly sulfated form of HS, is more extensively modified and more uniformly sulfated over the whole chain. HS is found on almost all cell surfaces, including endothelial cells, whereas heparin is only found within granules in connective tissue mast cells.
About 50% of rosettes formed by cultured strains or fresh isolates have been found to be sensitive to the disruption by HS and heparin. 13, 16, 17 Furthermore a heparinase III sensitive receptor has been suggested to be involved in formation of rosettes. 16 The capacity to bind heparin to the pRBC surface has also been found to be relatively common among clinical samples and associated with the severity of disease. 23 DBL1 of FCR3S1.2, an N-terminally located domain of PfEMP1 present in almost all PfEMP1 known to date 24 , has been demonstrated to be a heparin binding protein. 16, 25 The finding that DBL1 also interacts with GAGs from other sources 15, 25 suggested to us that HS might be implicated in the cytoadherence of pRBC to vascular endothelial cells. In this study we show that human endothelial cell surface HS indeed functions as a receptor in the cytoadherence of pRBC of FCR3S1.2 as well as of wild clinical isolates from Uganda. In addition, the binding to HS was found to be via the N-terminal DBL1 domain, which for the first time is demonstrated to be involved in cytoadherence.
For
METHODS

Parasites
The parasite FCR3S1.2 15 , a highly rosetting clone obtained from FCR3S1 by micromanipulation, was used in all the experiments. The rosetting rate was routinely >75%.
The parasites were cultivated in malaria culture medium (RPMI-1640-HEPES, 25 mmol/L sodium bicarbonate, 10 µg/mL gentamycin) containing 10% human serum (blood group AB Rh-positive) according to standard procedures. 26, 27 The P. falciparum clinical isolates U10, U11-1, U11-2, U14; U15, U18, U22-1, U22-2, and U26, were obtained from venous blood sample taken from malaria patients in Kampala, Uganda. In all cases, informed consent was obtained from the patients and/or their parents. The erythrocytes were immediately separated from mononuclear cells on Polymorphprep (Axis-Shield) and washed in RPMI. Nonimmune AB Rhpositive serum to a final hematocrit of 40% and freezing media (28% glycerol, 3% sorbitol, 0.65% NaCl) to a 1:1 ratio were added before freezing the cells in liquid N 2 .
For the assays, the freshly frozen isolates were thawed and cultured in malaria culture medium in their own blood containing 15% human serum (blood group AB Rhpositive) until they had matured into trophozoites.
26
Cells
Human umbilical vein endothelial cells (HUVEC) were isolated from fresh umbilical cords obtained from the Karolinska Hospital, Stockholm, as previously described. 28 Briefly, human umbilical veins were flushed with phosphate-buffered saline (PBS), then filled with PBS containing 0.2% trypsin and incubated for 30 min at room temperature. The HUVECs were removed from the vein by PBS wash, and the trypsin solution was added to HUVEC medium (MCDB-131 medium, 25 mmol/L HEPES,
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From 7 0.2% NaHCO 3 , 10 ng/mL epidermal growth factor (Sigma), 1 µg/mL hydrocortisone (GIBCO)), containing 10% fatal calf serum (FCS). Other HUVEC preparations used were purchased from Cytotech, Nivaa, Denmark. Cells were grown in HUVEC medium supplemented with 5% FCS. Human lung endothelial cells (HLEC) were a generous gift from Artur Scherf and Jürg Gysin. HLEC were grown in HLEC-medium (DME/F12 medium, 1.2 g/L sodium bicarbonate, 10 mg/L gentamicine, 15 µg/mL endothelial cell growth supplement (BD Biosciences)) containing 10% fetal bovine serum.
Polysaccharides
GAGs were radiolabeled by N-3 H-acetylating free amino groups to a specific activity of 125.000 cpm/ g, 70.000 cpm/ g and 475.000 cpm/ g for bovine lung heparin, swine liver HS and swine intestine HS respectively, as described. 29 Selective chemical modification of bovine lung heparin was prepared as described previously. 29, 30 The proteoglycan pool from HUVEC was purified from Na 2 35 SO 4 (NEN) metabolically labeled cells essentially as described. 31 To isolate the GAGs HS and CS from the intact proteoglycan, a proteolytic digestion of the core proteins with pronase E (0.3 mg/mg protein) was performed. In order to purify HS from the GAG pool CS was cleaved off with chondroitinase ABC followed by anion exchange chromatography as described. 31 CS was isolated by treating the GAG pool with nitrous acid at pH 1.5 to cleave HS, followed by separation on anion exchange chromatography. Heparin, HS and CSA from porcine intestine used in rosetting-, cytoadherence-and immunofluorescence-assays were obtained from Løvens Kemiske Fabrik (Ballerup, Denmark). Bovine lung heparin was a gift from Pharmacia, Kalamazoo, MI and was purified as described. 32 HS from swine liver and swine intestine were purified as 
Expression of recombinant PfEMP1 domains
Geneconstructs encoding three PfEMP1 domains (DBL1 , CIDR1 , DBL2 ) of FCR3S1.2 were expressed as glutathione S-transferase (GST) fusionproteins and purified as described. 16 Briefly, the pGEX-4T-1 system was used and individual 
Cytoadherence assay
The cytoadherence assay was performed as described 27 with some modifications. Giemsa for 1 h at room temperature. 300-500 endothelial cells were counted in order to estimate the number of bound pRBC per cell using light microscopy (Nikon, Optiphot-2, Japan) at an x1000 magnification. 
Rosette disruption assay
The assay was performed essentially as described. 27, 33 Briefly, GAGs (0.001-1 mg/mL) were added to 25 µl aliquots of a rosetting FCR3S1.2 culture in a micro-titer plate. The mixture was incubated for 30 minutes at 37°C. The rosetting-rate was subsequently estimated after staining with acridine orange and compared with mocktreated controls. The level of rosetting was expressed as the number of rosette-forming late-stage pRBC per total number of late-stage pRBC x100.
Immunofluorescence
HUVEC or HLEC were detached from the culture flasks with a "rubber policeman"
and resuspended in PBS to a cell density of 2-4 x 10 6 . HUVEC were used with or without 0.3% bovine serum albumin (BSA). Fusion proteins including GST-DBL1 , GST-CIDR1 or GST alone were added at 50, 100 or 200 µg/mL to the cells and 
Binding of GAGs to pRBC
Trophozoite-infected erythrocytes (2x10 8 
Binding of GAGs to recombinant PfEMP1 domains
DBL1 -GST, CIDR1 -GST, DBL2 -GST or GST alone were coupled to a 1 mL Figure   1A and B). When the HUVECs were pretreated with heparinase III to remove HS from the cell surface, adhesion decreased by more than 70% (73.5%, Figure 1C To confirm that the use of a HS receptor is not only true for the cloned parasite FCR3S1.2, wild clinical isolates from Uganda were analyzed. Out of nine isolates eight grow into mature trophozoites, with parasitemia ranging between 2.2-7.2%.
These were tested for binding to HUVEC. Four of these eight isolates, U10, U11-2, U14, and U18 showed adhesion over 100 pRBC per100 cells (140, 207, 101 and 232 pRBC per 100 cells, respectively, Table 1 ). These were considered as binders to HUVEC and are further discussed. Those isolates generating lower cytoadherence than 100 pRBC per 100 cells were considered as non-binders to HUVEC in this study (U11-1, U15, U22-1, U22-2 with 51, 11, 6 and 38 pRBC per 100 cells, respectively).
After heparinase III treatment of the target cells U10, U11-2, U14, and U18 decreased 
HS blocks the adhesion of pRBC to endothelial cells
In a complementary assay, we tested whether soluble GAGs could compete for the binding of pRBC to endothelial cells. To estimate the competing effect of the different GAGs, HS, heparin and CSA (0.1 µg/mL -10 mg/mL) were added together with the infected erythrocytes (FCR3S1.2) to HUVEC and HLEC in the cytoadherence assay.
HS and heparin did inhibit adhesion to HUVEC in a dose dependent manner, whereas CSA had no effect even at the highest concentrations tested (Figure 2A ).
Cytoadherence of pRBC to HLEC was also affected by the addition of the GAGs HS and heparin in a dose dependent manner ( Figure 2B ). On HUVEC, HS was found to be more effective than heparin in the cytoadhesion assay with an IC 50 of 0.3 mg/mL as compared to 1.2 mg/mL for heparin. The opposite was found on HLEC on which heparin was a more effective inhibitor than HS with an IC 50 of 1 mg/mL for heparin.
The IC 50 for HS could not be determined at the concentrations tested ( Figure 1B) . In parallel the same GAG preparations were examined for inhibition of rosette formation ( Figure 2C ). For rosette disruption heparin was here a better inhibitor than HS.
Heparin inhibited rosetting with an IC 50 of 0.02 mg/mL, whereas HS did not completely inhibit rosetting even at the highest concentration tested.
The effect of GAGs on cytoadherence of wild clinical isolates from Uganda was analyzed on the isolates based on the same criteria as above (U-10, U11-2, U14, and U18). Isolates U10 and U14 decreased by 44% and 54% after adding 1 mg/ml HS and by 54% and 94% upon addition of 1 mg/ml heparin, respectively (Table 1) . Heparin (1 mg/mL) affected cytoadhesion of sample U11-2 and binding decreased by 36%, 14 whereas double HS concentration was needed to exert a modest effect. No loss of adhesion was seen in sample U18 by any of the GAGs.
Two different domains of PfEMP1 mediate binding to HS and PECAM-1/CD31
Since PECAM-1/CD31 is a known receptor involved in cytoadherence of pRBC and is expressed by HUVEC, we wanted to examine the relative involvement of PECAM-1/CD31 and HS as receptors for pRBC of FCR3S1.2. The interaction between recombinant domains of PfEMP1 and the receptors when located on human endothelial cell surface was studied. The two most N-terminal domains of PfEMP1 var1 , DBL1 and CIDR1 , were tested for binding to HUVEC using an immunofluorescence assay as described above. Recombinant GST-fusion proteins of DBL1 or CIDR1 were incubated with HUVEC cells and the adhesion was detected using a fluorescent antibody to GST. Strong fluorescence was observed when DBL1 and CIDR1 bound to normal HUVEC whereas GST alone did not bind to the cells ( Figure 3A-B , F-G, and data not shown). When the HUVECs were pretreated with heparinase III to remove cell surface HS, no binding was detected with DBL1 ( Figure 3C ) whereas CIDR1 continued to bind well to the HS-free cells ( Figure 3H ).
In contrast, incubation of the cells with an anti-PECAM-1/CD31 antibody blocking PECAM-1/CD31 on the cell surface abolished binding of CIDR1 ( Figure 3I ) but not binding of DBL1 ( Figure 3D ). DBL1 did also bind to HLEC in HS-sensitive manner ( Figure 3K-M) . With these results we show for the first time that DBL1 acts as a ligand to an endothelial receptor and add HS to the receptor-map of DBL1 for cytoadherence, but also confirm earlier data with PECAM-1/CD31 as a CIDRreceptor. 15 The role of HS as a receptor for DBL1 but not for CIDR1 could be further confirmed by competition of adhesion with soluble HS ( Figure 3E and J, 
S-labeled human endothelial HS binds to infected erythrocytes and to DBL1
To be able to study the binding properties of the receptor purified from host target cells, human endothelial GAGs were purified. HUVECs were metabolically labeled with 35 HUVEC HS and heparin bound avidly to DBL1 ( Figure 5A and B) , but not to CIDR1 nor to DBL-2 ( Figure 5D, E, G and H) . The major fraction of bound endothelial HS eluted from the DBL1 column at 0.4 mol/L NaCl, the same concentration of salt as required to elute heparin from DBL1 . Endothelial CS did not bind to any of the domains ( Figure 5C, F and I) , nor did any of the GAGs interact with GST (data not shown). domains. Together, these findings prove that DBL1 is involved in cytoadherence through binding to a HS receptor, in addition to serving as a ligand in rosetting.
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Our finding of HS as an endothelial receptor for pRBC may at first glance seem to be in conflict with previous work that suggested that HS does not influence cytoadherence. 34 These authors argued that an HS receptor could not be an endothelial receptor for pRBC since heparinase treated target cells did not show decreased cytoadherence. In their study heparinase I was used, an enzyme that is specific for
IdoA2S within an N-sulfated sequence as found in highly sulfated sequences of HS and heparin, yet rare in HS of human endothelial cells. 35 Heparinase I treatment will therefore leave the HS-chains on endothelial cells only partially digested likely with enough sites remaining on the cell surface for the parasite to attach. The parasite lines used were HB3EC-6 and HB3C32 both known to bind CD36 but off an unknown heparin or HS-binding status.
HS is expressed as protein-bound sugar chains in a tissue and species specific pattern providing binding sites for a wealth of endogenous molecules 32 and exogenous invaders such as protozoa, bacteria, or viruses. 36 The biosynthetically controlled fine structure of HS creates a sophisticated tissue pattern as demonstrated by the tissuestaining pattern using diverse anti-HS-antibodies 21, 22, 37, 38 or growth factor molecules. 39, 40 GAGs like heparin and CSA have previously been implicated in the reversion of sequestration in vitro and ex vivo by affecting either cytoadherence 41, 42 or rosetting 13, 16, 23, 25 of pRBC. With this substantiation it is important to investigate
GAGs from different origins.
Both HS and heparin were found to block cytoadherence to HUVEC and HLEC. The higher concentrations of HS and heparin needed to affect adhesion to HLEC as compared to HUVEC (Figure 2A and B) is most likely due to the different receptor ensembles available on their cell surfaces. For example CD36, a receptor involved in cytoadherence 5 is present on HLEC but is lacking on the HUVEC. HS was found to effectively block cytoadherence to HUVEC at approximately 10-fold lower
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From concentration then in rosette formation while the opposite was true for heparin 16 ( Figure 2A and C) . This may suggest a distinct binding specificity of DBL1 for endothelial and erythrocyte receptors. Another reason for the higher concentration of heparin vs. HS needed in blocking cytoadherence to HUVEC may be that heparin binds to cellular receptors on the endothelial cells and thereby enhances parasite adhesion at low concentrations of added heparin. This would also reduce the effective inhibitor concentration compared to HS, as suggested by our experiments and also supported by experiments performed by McCormick and co-workers. 43 These authors found that heparin could contribute to enhanced cytoadherence by acting as a bridge between PfEMP1 and CD36 on transfected CHO cells. Although this enhancing phenomenon was not found on the CD36 expressing HLEC, a similar effect was observed in our study using HUVECs, even though these cells do not express CD36.
When heparin was added at very low concentrations to normal HUVEC the binding increased by ~20 % (Figure 2A ) while at higher concentrations heparin effectively inhibited binding. This might suggest that a heparin binding cell surface protein is available on HUVEC, which after interaction with heparin would function as an "introduced" GAG receptor for pRBC.
PECAM-1/CD31, another receptor that contributes to cytoadherence of FCR3S1.2 6 , is present on HUVEC. 44 In agreement with previous results CIDR1
binds PECAM-1/CD31 15 ( Figure 3 ). This receptor is responsible for the adhesion independent of HS. It was not competed by HS and remained after heparinase III treatment of HUVEC, yet could be completely inhibited by anti-PECAM-1/CD31
antibody. The total inhibition of cytoadherence achieved with high concentrations of either heparin or HS on one hand and anti-PECAM-1/CD31 antibodies alone on the other hand is most likely due to steric hindrance of the respective domains in PfEMP1 Malaria parasites from patients are not clonal in nature, yet a large number of patient blood samples contain GAG binding parasites. 17, 23 As much as 50% of rosettes formed by fresh isolates have been shown to be sensitive to the disruption by HS and heparin. 13, 16, 17 In another study using fresh wild isolates it was found that more then 80% of the isolates tested (90 out of 111 samples analyzed) bound to heparin, which could be associated to severity of disease. 23 Clinical isolates were in 
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